UY34132A - Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. - Google Patents

Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.

Info

Publication number
UY34132A
UY34132A UY0001034132A UY34132A UY34132A UY 34132 A UY34132 A UY 34132A UY 0001034132 A UY0001034132 A UY 0001034132A UY 34132 A UY34132 A UY 34132A UY 34132 A UY34132 A UY 34132A
Authority
UY
Uruguay
Prior art keywords
pyridopirimidinone
malignal
neoplasias
bendamustine
pi3k
Prior art date
Application number
UY0001034132A
Other languages
English (en)
Inventor
Decillis Arthur
Lager Joanne
Zaks Tal
Original Assignee
Sanofi Sa
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Exelixis Inc filed Critical Sanofi Sa
Publication of UY34132A publication Critical patent/UY34132A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

La invención proporciona un método para el tratamiento de cánceres incluyendo neoplasias malignas h ematológicas que comprende administrar un compuesto de Fórmula I, en combinación con uno o ambos de bendamustina y rituximab.
UY0001034132A 2011-06-15 2012-06-15 Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab. UY34132A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161497356P 2011-06-15 2011-06-15
US201161510324P 2011-07-21 2011-07-21
FR1255114 2012-06-01

Publications (1)

Publication Number Publication Date
UY34132A true UY34132A (es) 2013-01-31

Family

ID=47357478

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034132A UY34132A (es) 2011-06-15 2012-06-15 Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.

Country Status (9)

Country Link
US (1) US20140302012A1 (es)
EP (1) EP2793892A1 (es)
JP (1) JP2014517042A (es)
CN (1) CN103874494A (es)
AR (1) AR086955A1 (es)
RU (1) RU2014101071A (es)
TW (1) TW201306842A (es)
UY (1) UY34132A (es)
WO (1) WO2012174327A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106420743A (zh) 2010-07-16 2017-02-22 埃克塞里艾克西斯公司 C‑met调节剂药物组合物
WO2012037204A1 (en) 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
BR112013020362A2 (pt) 2011-02-10 2018-05-29 Exelixis Inc processos para a preparação de compostos de quinolina, compostos e combinações farmacêuticas que os contem
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
KR20140025496A (ko) 2011-05-02 2014-03-04 엑셀리시스, 인코포레이티드 암 및 뼈 암 통증의 치료방법
BR112014006702A2 (pt) 2011-09-22 2017-06-13 Exelixis Inc método para tratar osteoporose
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
CN107375289A (zh) 2011-11-01 2017-11-24 埃克塞利希斯股份有限公司 用于治疗淋巴组织增生性恶性肿瘤的作为磷脂酰肌醇3‑激酶抑制剂的化合物
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
TW201521792A (zh) * 2013-03-05 2015-06-16 Sanofi Sa ＰＩ３Ｋα抑制劑之錠劑調配物
MX366003B (es) 2013-03-15 2019-06-24 Exelixis Inc Metabolitos de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n' -(4-fluorofenil)ciclopropan-1,1-dicarboxamida.
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
GB201321717D0 (en) 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
MX2021001583A (es) 2014-02-14 2023-02-08 Exelixis Inc Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
US10159666B2 (en) 2014-03-17 2018-12-25 Exelixis, Inc. Dosing of cabozantinib formulations
MA40250A (fr) * 2014-07-04 2017-05-10 Lupin Ltd Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
CN106715397B (zh) 2014-07-31 2021-07-23 埃克塞里艾克西斯公司 制备氟-18标记的卡博替尼及其类似物的方法
EP3177311A1 (en) 2014-08-05 2017-06-14 Exelixis, Inc. Drug combinations to treat multiple myeloma
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
LT3497103T (lt) * 2016-08-15 2021-07-26 Pfizer Inc. Piridopirimidinono cdk2/4/6 inhibitoriai
WO2018060804A1 (en) 2016-09-29 2018-04-05 Telefonaktiebolaget Lm Ericsson (Publ) Active time handling with 2-step granting

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
BRPI0617159B8 (pt) * 2005-10-07 2021-05-25 Exelixis Inc compostos de piridopirimidinone inibidores de pi3ka, composições que os contem e processo para preparo
WO2008032162A1 (en) * 2006-09-15 2008-03-20 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors
UA100979C2 (ru) * 2007-04-10 2013-02-25 Экселиксис, Инк. Применение пиридопиримидиноновых ингибиторов pi3k альфа для лечения рака
WO2012065019A2 (en) * 2010-11-12 2012-05-18 Exelixis, Inc. Pyridopyrimidinone inhibitors of p13k alpha

Also Published As

Publication number Publication date
CN103874494A (zh) 2014-06-18
AR086955A1 (es) 2014-02-05
WO2012174327A1 (en) 2012-12-20
JP2014517042A (ja) 2014-07-17
TW201306842A (zh) 2013-02-16
EP2793892A1 (en) 2014-10-29
US20140302012A1 (en) 2014-10-09
RU2014101071A (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
UY34132A (es) Terapias combinadas para el tratamiento de neoplasias malignas hematológicas utilizando inhibidores de piridopirimidinona de pi3k/mtor con bendamustina y/o rituximab.
ECSP14013284A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016001082A1 (es) Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa
MX2016002974A (es) Eteres de arilo y sus usos.
CL2015002932A1 (es) Inhibidores de proteína quinasa
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34763A (es) Inhibidores de la agregación plaquetaria
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
UY34045A (es) Derivados de imidazopiridina como inhibidores de pi3k
AR089993A1 (es) Macrociclos peptidomimeticos
UY35500A (es) Indazoles sustituidos con heteroarilo
UY34145A (es) Compuestos inhibidores de metaloenzimas
UY34146A (es) Compuestos inhibidores de metaloenzimas
UY33925A (es) Inhibidores tricíclicos de quinasas
CL2015001246A1 (es) Derivados de bendamustina y los metodos de su uso
UY34541A (es) ?derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina?.
UY34550A (es) Bencilpirazoles sustituidos
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
UY34138A (es) Antagonistas de trpv4
UY34812A (es) Método para el tratamiento del cáncer de pulmón de células no pequeñas
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
CR20140367A (es) Inhibidores de iap

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020